Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AFX 1251

Next Previous
Drug Profile

AFX 1251

Alternative Names: AFX-1251

Latest Information Update: 28 Feb 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Afecta Pharmaceuticals; University of California at Irvine
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Proto-oncogene protein b-raf modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Malignant melanoma

Most Recent Events

  • 28 Feb 2024 No recent reports of development identified for preclinical development in Malignant-melanoma in USA
  • 20 Jan 2020 Preclinical trials in Malignant melanoma in USA (Afecta Pharmaceuticals pipeline, January 2020)
  • 05 Apr 2019 Afecta Pharmaceuticals enters into a research collaboration with University of California for Malignant melanoma

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top